Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, Sept. 22, 2008 (GLOBE NEWSWIRE) -- Asphelia Pharmaceuticals, a privately held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological...
-
SAN DIEGO, Sept. 10, 2008 (GLOBE NEWSWIRE) -- Asphelia Pharmaceuticals announced today that several pre-eminent medical practitioners and scientists in the fields of immunology, gastroenterology,...
-
SAN DIEGO, June 10, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological...
-
SAN DIEGO, May 2, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on developing novel therapeutics for the treatment of a variety of immunological...
-
MADISON, Wis., April 7, 2008 (PRIME NEWSWIRE) -- As announced in the March 7th issue of the Wisconsin State Journal, Dr. John Fleming, a leading neurologist at the UW Hospital, is initiating an...
-
SAN DIEGO, Sept. 27, 2007 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, Inc., a Paramount BioSciences-founded company committed to the development of new treatments for patients living with...